Rapid Takeaways From Late-Breaking Science at EuroPCR 2024 | SCAI

Early Outcomes of a Randomized Non-Inferiority Trial Comparing TAVI Devices: The LANDMARK Trial

The developing world has an epidemic of heart disease, and alternative options may help with delivery of care and cost. The LANDMARK trial looks at the latest balloon expandable platform, Myval, which was developed in India as an alternative transcatheter aortic valve implantation (TAVI or TAVR) valve. 

First TAVI vs. SAVR Randomized Trial in Younger Low-Risk Patients With Severe Tricuspid or Bicuspid Aortic Valve Stenosis: Results From NOTION-2

This study at EuroPCR explored the clinical outcomes in low-risk and young (75 years or younger) aortic stenosis (AS) patients treated with TAVR and SAVR, including those with both tricuspid and bicuspid AS. 

Long-Term Outcomes of Transcatheter Aortic Valve vs. Surgical Aortic Valve Replacement

A new study published in JSCAI and presented at EuroPCR demonstrates the long-term safety and efficacy of a minimally invasive procedure to replace the aortic valve in the heart—transcatheter aortic valve replacement (TAVR)—compared to surgical aortic valve replacement (SAVR). 

OCT vs. Angiography for Guidance of Calcified Lesions PCI: The CALIPSO Trial 

The use of optical coherence tomography (OCT) for plaque characterization and preparation guidance has been advocated versus conventional methods to improve calcified lesions percutaneous coronary intervention (PCI) outcomes. The CALIPSO trial aimed to assess the technical outcome superiority of OCT over angiography alone for calcified lesions PCI guidance.  

One-Month DAPT Followed by 5-Month Ticagrelor Monotherapy in Acute Coronary Syndromes With DCB

Patients treated with DCB theoretically require less intense antiplatelet therapy. However, to date, there are no randomized data exploring the tailored antiplatelet strategies for these patients and a lack of guideline recommendations. The study presented at EuroPCR was an open-label, investigator-initiated, noninferiority trial at 41 sites in China. 

What's Happening at SCAI

Updates on the Society's publications, advocacy initiatives, fundraising, professional recognition programs, research, and collaborations with partners.